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Abstract
Purpose The purpose of this review is to summarize
current knowledge of detailed biochemical evidence for the
role of c-aminobutyric acid type A receptors (GABAA–Rs)
in the mechanisms of general anesthesia.
Principal ﬁndings With the knowledge that all general
anesthetics positively modulate GABAA-R-mediated inhib-
itory transmission, site-directed mutagenesis comparing
sequences of GABAA-R subunits of varying sensitivity led
to identiﬁcation of amino acid residues in the transmem-
brane domain that are critical for the drug actions in vitro.
Using a photo incorporable analogue of the general
anesthetic, R(?)etomidate, we identiﬁed two transmem-
brane amino acids that were afﬁnity labelled in puriﬁed
bovine brain GABAA-R. Homology protein structural
modelling positions these two residues, aM1-11’ and bM3-4’,
close to each other in a single type of intersubunit etomi-
date binding pocket at the b/a interface. This position
would be appropriate for modulation of agonist channel
gating. Overall, available information suggests that these
two etomidate binding residues are allosterically coupled
to sites of action of steroids, barbiturates, volatile agents,
and propofol, but not alcohols. Residue a/bM2-15’ is
probably not a binding site but allosterically coupled to
action of volatile agents, alcohols, and intravenous agents,
and a/bM1-(-2’) is coupled to action of intravenous agents.
Conclusions Establishment of a coherent and consistent
structural model of the GABAA-R lends support to the
conclusion that general anesthetics can modulate function
by binding to appropriate domains on the protein. Genetic
engineering of mice with mutation in some of these
GABAA-R residues are insensitive to general anesthetics in
vivo, suggesting that further analysis of these domains
could lead to development of more potent and speciﬁc
drugs.
Re ´sume ´
Objectif L’objectif de cet article de synthe `se est de
re ´sumer les connaissances actuelles concernant les
donne ´es probantes biochimiques de ´taille ´es e ´lucidant le
ro ˆle des re ´cepteurs a ` l’acide c-aminobutyrique de type A
(R-GABAA) dans les me ´canismes de l’anesthe ´sie ge ´ne ´rale.
Constatations principales Tous les anesthe ´siques
ge ´ne ´raux modulent positivement la transmission inhibitrice
me ´die ´e par les R-GABAA. On a identiﬁe ´ les acides amine ´s
du domaine transmembranaire repre ´sentant des sites
d’action importants des me ´dicaments, en effectuant des
mutations cible ´es sur des se ´quences de sous-unite ´s des
R-GABAA et en comparant leur sensibilite ´.A ` l’aide d’un
analogue photo luminescent de l’anesthe ´sique ge ´ne ´ral
e ´tomidate R(?), nous avons identiﬁe ´ deux acides amine ´s
transmembranaires marque ´es par afﬁnite ´ dans les
R-GABAA puriﬁe ´s de cerveau bovin. Un mode `le structurel
de prote ´ine par homologie place ces deux re ´sidus, soit
aM1-11’ et bM3-4’, a `proximite ´l’un de l’autre dans un type
unique de poche de liaison d’e ´tomidate inter-sous-unite ´au
niveau de l’interface b/a. Cette position sera adapte ´e pour
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DOI 10.1007/s12630-010-9429-7moduler le portillon des canaux agonistes. Globalement,
les donne ´es disponibles sugge `rent que des deux re ´sidus se
liant a ` l’e ´tomidate sont couple ´s de fac ¸on alloste ´rique aux
sites d’action des ste ´roı¨des, des barbituriques, des agents
volatils et du propofol, mais pas a ` ceux des alcools. Le
re ´sidu a/bM2-15’ n’est probablement pas un site de
liaison, mais il est couple ´ de fac ¸on alloste ´rique a ` l’action
des agents volatils, des alcools et des agents intraveineux,
et le a/bM1-(-2’) est couple ´ a ` l’action des agents
intraveineux.
Conclusion La cre ´ation d’un mode `le structurel cohe ´rent
et logique des R-GABAA appuie notre conclusion selon
laquelle les anesthe ´siques ge ´ne ´raux peuvent moduler leur
fonction en se liant a ` des domaines spe ´ciﬁques sur la
prote ´ine. Les souris ge ´ne ´tiquement modiﬁe ´es porteuses
d’une mutation dans certains de ces re ´sidus de R-GABAA
ne sont pas sensibles aux anesthe ´siques ge ´ne ´raux in vivo,
ce qui sugge `re qu’une analyse plus approfondie de ces
domaines pourrait permettre la mise au point de
me ´dicaments a ` la fois plus puissants et plus spe ´ciﬁques.
The purpose of this review is to inform the reader of the
current knowledge of detailed biochemical evidence for the
role of c-aminobutyric acid type A receptors (GABAA–Rs)
in the mechanisms of anesthesia. We brieﬂy summarize the
evidence connecting anesthetic action on the brain with
action on GABAA-Rs and the structure and function of
GABAA-Rs. We describe the major techniques utilized for
determination of amino acids and sequence domains within
proteins that participate in various functions, and we
summarize the newest data developed on the study of
GABAA-Rs to identify such sites. We also discuss how the
overall data for all the chemical classes of general anes-
thetics either form or do not form a coherent story for a role
for GABAA-Rs in anesthetic action and its relevance for
the future of clinical anesthesiology.
Most drugs that act as general anesthetics act only at
relatively high concentrations, and their interaction with
biosystems has long been considered as more of a physical
interaction, namely, perturbation of ﬂuidity of the mem-
brane lipid bilayer, which is consistent with the Meyer-
Overton correlation. In this correlation, potency as a general
anesthetic is directly related to the solubility ratio for the
compound in an oil-water mixture rather than to chemically
speciﬁc binding to recognition sites on the molecules
involved, as in traditional drug receptors.
1 However, recent
electrophysiological studies on speciﬁcity of action of
anesthetic agents on biosystems and biochemical investi-
gations on speciﬁc interactions with proteins, especially
membrane channels, suggest that general anesthetics prob-
ably act via hydrophobic regions of protein targets in
neurons.
2,3 A major candidate for the target of general
anesthetics is the GABAA receptor, a ligand-gated chloride
ion channel receptor for the neurotransmitter GABA, which
universally inhibits neuronal excitability via synaptic phasic
currents as well as extrasynaptic tonic currents.
4-7 The
GABAA -Rs are actually a family of heteropentamers with
differing subunit composition that vary in their age-
dependence and brain and subcellular localization of
expression and trafﬁcking, as well as their pharmacological
speciﬁcity, including sensitivity to GABA agonists and
allosteric modulators, such as benzodiazepines, general
anesthetics, neurosteroids, and ethanol (EtOH).
8,9
General anesthetic action and GABAA-Rs
Most if not all general anesthetics at relevant concentrations
enhance the function of GABAA-Rs, and GABAA-Rs are
positioned in the nervous system where they can mediate
anesthesia.
3,7,10-12 People have used the differential sensi-
tivity of GABAA-R subunits to anesthetic modulation,
especially the low sensitivity of q subtypes, to attempt to
identify amino acid residues in the GABAA-R subunit
sequences that are critical for anesthetic modulation.
13,14
The residues implicated are in or near the transmembrane
domains.Virtually all of the chemical classes of adrugs with
general anesthetic activity are implicated, including espe-
cially all of the intravenously administered agents, such as,
etomidate, propofol, barbiturates, steroids, and alcohols, as
well as the volatile gaseous agents. Some of these trans-
membrane GABAA-R residues have been mutated in
knock-in mice, which subsequently lose sensitivity to gen-
eral anesthetics, thus verifying the important role of
GABAA-Rs in anesthetic action.
12
Alcohol action and GABAA-Rs
Ethanol does enhance GABAA-Rs and glycine receptors,
much like longer chain alcohols (e.g., n-octanol), but at
very high (anesthetic) concentrations. We need to distin-
guish between these anesthetic effects of high-dose EtOH
and longer chain alcohols and the intoxicating effects of
lower doses, such as those encountered in the human brain
during social drinking, because evidence suggests that
effects of low- and high-dose EtOH involve (at least) two
distinct targets in the brain. We suggest that these receptors
that are sensitive to EtOH levels resulting from one glass
of wine (3-30 mM) are certain subtypes of GABAA-R, the
d subunit-containing extrasynaptic GABAA-R that mediate
tonic inhibition.
15,16 One major target of anesthetic doses
of EtOH (30-100 mM) is in the transmembrane domain of
GABAA-Rs and glycine receptors.
13,17,18
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interaction with GABAA-R that is relevant to its pharma-
cological actions at low doses as produced in humans by
one glass of wine.
16 Studies on a naturally-occurring allele
in the rat GABAA-R a6 subunit suggests that the residue,
a4/6R100, is involved in EtOH action as well as its
blockade by the benzodiazepine ligand, Ro15-4513.
17,19,20
These results are consistent with our observations that the
a4/6b3d subtypes of GABAA-R are more sensitive to EtOH
(low mM) than other subtypes, including the c2 subunit or
the b1/2 subunits.
15 Moreover, this is consistent with the
observation by many that EtOH at low mM concentrations
enhances GABAA-R-mediated tonic inhibitory currents in
cells expressing the d GABAA-R subunit.
19,21-23 This
hypothesis remains controversial,
24 as the expression of
recombinant d subunits is very difﬁcult and thus hardly
studied, and the brain slice/neuron work is still in its
infancy; however, we believe the hypothesis will be
accepted as it becomes better understood. Our preliminary
investigations of domains within the b3 and d subunits
that interact in a4/6b3d subtypes implicate residues in the
b3 subunit that are homologous to the benzodiazepine
binding site involving aR100, which produces an EtOH-
sensitive binding site for certain benzodiazepines, like
Ro15-4513, that would be located at the a?/b- interface in
the extracellular domain. Future work will determine
whether this model has any basis in reality.
Methods for identiﬁcation of amino acids involved
in speciﬁc functions of proteins, including allosteric
modulators
Chimeras and site-directed mutagenesis
An often utilized and frequently successful technique is to
compare polypeptide sequences of homologous subunits
showing varying sensitivity to drugs. For example, Mihic
et al.
13 compared glycine receptors (sensitive to isoﬂurane
and high-dose EtOH) with GABAA-R q subunits (insen-
sitive to these modulators). One makes chimeric cDNAs
that differ in the domain of interest and determine which
residues are critical. This is followed by site-directed point
mutations in suspected residues until the critical one(s) is
identiﬁed. On the negative side, identiﬁcation of residues
that determine modulatory drug sensitivity by mutagenesis
alone may be allosterically coupled to the function rather
than involved in binding per se. Thus, the initial observa-
tion requires conﬁrmation by secondary approaches. This
could involve studying a number of mutations for the
implicated residue to discover the shape and properties the
‘‘pocket’’ might show, or attempting a covalent couple of
an analogue of the anesthetic containing a sulfhydryl
reagent to the cysteine-substituted candidate residue.
25-27
Afﬁnity labelling
The use of afﬁnity labels is more likely to identify residues
involved in a binding pocket, because the ligand has to
have reasonable afﬁnity for the target protein and a
chemical group that will bind the protein covalently. The
ligand will label residues in close contact when it is bound
to the receptor. To maximize speciﬁcity, the chemically
reactive group is often stable until chemically activated,
e.g., by ultraviolet light.
28 Nevertheless, some uncertainty
arises from possible movement of the activated ligand from
the binding site to nearby areas, depending on its lifetime
and relative reactivity. Thus, additional evidence consistent
with identiﬁcation of the labelled residues as binding site
constituents is also useful here. Making the afﬁnity label
radioactive can allow identiﬁcation of the subunit poly-
peptide-carrying binding sites on SDS gels and can aid in
sequencing the peptide. This binding must be prevented by
excess non-radioactive ligand, and its relevance to the drug
receptor can be supported by evidence of allosteric mod-
ulation of its binding by other receptor ligands. Another
advantage of afﬁnity labelling is the fact that the results are
unbiased by having to guess in advance which residues
might be important, as required with mutagenesis. We
succeeded in using this technique for anesthetic binding to
GABAA-R.
29
Major ﬁndings
Site-directed mutagenesis results
Wingrove et al. (1994)
30 found that modulation of GABAR
by the anticonvulsant/anxiolytic loreclezole depended on
the nature of the b subunit (b2/b3  b1). Belelli et al.
(1997)
31 extended this b subunit selectivity to the intra-
venous anesthetic, etomidate, a chemical analogue of
loreclezole, and demonstrated that the b selectivity was due
to residue 265, which is N in both b2 and b3 (sensitive to
etomidate) and differed from b1 (S, insensitive to etomi-
date) as well as the insect b (Rdl, which has M, insensitive
to etomidate). They
31 showed that a single amino acid in
GABAA-R, b2N265, (bM2-15’) was responsible for the
selectivity of b2 and b3 over b1 for the modulatory drugs,
loreclezole and etomidate. This b selectivity was found to
extend to the related intravenous anesthetic, propofol.
32
Mihic et al. (1997)
13 used the anesthetic-insensitive
GABAA-R q subunit sequence and the anesthetic-sensitive
glycine receptor a and GABAR a and b subunits to iden-
tify, by construction of chimeras and point mutations, some
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123amino acid residues critical for modulation of GlyR and
GABAA-R by volatile anesthetics and long-chain alcohols,
implicating the M2-15’ and M3-4’ residues in both the a
and b subunits of GABAA-R. Note that the M2-15’ residue
is the same as the one found simultaneously by Belelli
et al. (1997).
31
Carlson et al. (2000)
14 took a similar approach to
identify a single amino acid at the entrance to M1(-2’) in
GABAA-R a and b, i.e., b2G229, which when mutated to
larger (e.g., F as in q) or charged residues gave signiﬁ-
cantly reduced sensitivity to modulation of binding and
function by steroids, etomidate, propofol, and barbiturates,
with enhanced direct gating by these drugs. Thus, it
appeared that larger than normal amino acids at this posi-
tion took the place of anesthetics in partially enhancing
GABA, so that the extent of enhancement by the exoge-
nous anesthetic ligand was reduced.
In addition to the residues identiﬁed by Mihic et al.
(1997)
13 for anesthetic doses of EtOH enhancement of
glycine receptors (transmembrane a1S267[M2-15’]), Daryl
Davies and Ron Alkana found that residues in the extra-
cellular domain loop 2 (a1A52) are also needed
33 and
proposedtobein thesamepocket asM2-15’.These workers
also went on to show that modiﬁcation of loop 2 in glycine
receptor a1 subunits or in GABAA-R c2 subunit, such as
replacement by the loop 2 10-residue peptide fragment from
the GABAA-R d subunit, increases EtOH sensitivity about
tenfold, as measured in oocyte recordings.
34
Hosie et al. (2006)
35 constructed chimeras replacing ste-
roid-sensitive a1a n db2 subunits of the GABAA-R M1 – M2
residues with those from the steroid-insensitive insect Rdl
clone; this reduced steroid modulation, potentiation of
GABA, and direct activation of abc receptors when a1w a s
mutated,butnotb2.Steroidmodulationwasshowntodepend
on the nature of several residues in the transmembrane helix.
They provided evidence that a1Q242(M1-10’) and a1N408
and Y411 in M4 (bovine numbering)
36 could provide anchor
points to bind the two ends of the steroid molecule. Also,
a1T237(M1-5’) (bovine numbering) and bY284 were shown
to be essential for direct activation, and protein structural
modellingsuggestedthattheywerelocatedneareachotherin
a single intersubunitpocketat the bM3-aM1interface.
35This
possible model is discussed further below.
Mouse knock-ins
The results of Belelli et al. (1997)
31 led to the production of
knock-inmice with pointmutationsinthissingleGABAA-R
subunit bM2-15’ residue. Both the b2N265S (replaced with
the b1 residue),
37 which showed less sensitivity to the sed-
ative action of etomidate, and the b3N265 M (replaced with
the anesthetic-insensitive insect residue),
38 which showed
less sensitivity to the immobilization action of etomidate
and propofol, provided strong evidence for the role of
GABAA-Rs in anesthetic action. Furthermore, a subunit
composition-dependent pharmacology was established,
presumably due to an anatomical correlate of anesthetic
sensitivity. In other words, the b3-containing GABAA-Rs
and the circuits in which they function are involved in the
anesthetic actions of etomidate, while the b2-containing
GABAA-Rs are not but are involved in some of the sedative
and other actions of etomidate; b1-containing GABAA-Rs
are not involved in anesthetic actions of etomidate.
12
Harrison et al. went on to test the a1S270H mutation in
knock-in mice for reduced sensitivity to anesthetics. Hall
et al. (2004)
39 found a reduced sensitivity to isoﬂurane in
enhancing GABAA-R current, with increased probability of
opening for the mutant channels in absence of anesthetic.
Elsen et al. (2006)
40 found altered responses to volatile
anestheticsin vivo,including reduced time ofanesthesiaand
abnormal seizure-like behaviours on coming out of anes-
thesia. This is not strong evidence for an anesthetic site of
action. However, the a1S270H (M2-15’) knock-in mice had
a sickly phenotype, interpreted as likely due to the left-shift
in the GABA dose-response curve and a corresponding
excessive GABAergic inhibition in vivo.
39 A compensatory
second knock-in point mutation, a1L277A, introduced into
the S270H mouse restored normal neuronal and in vivo
excitability levels, normal GABA sensitivity, and normal
health
41 and allowed demonstration that these animals
exhibited less than normal responses in some assays of vol-
atileanesthetic
42andhigh(anesthetic)-doseEtOHeffects.
43
Afﬁnity labelling with azietomidate
We have used the technique of photoafﬁnity labelling,
synthesizing a photo-incorporable analogue of etomidate
with anesthetic efﬁcacy, R(?)azietomidate, and then
radiolabelling it.
44 This ligand [
3H]azietomidate was suc-
cessfully employed to photolabel benzodiazepine afﬁnity-
puriﬁed GABAA-R proteins from cow brain and identify
two amino acids as sites of attachment.
29 The team led by
Keith Miller at Massachusetts General Hospital synthe-
sized a photo-incorporable anesthetic, R(?)azietomidate, a
close analogue of etomidate, and demonstrated both bio-
activity as well as photoafﬁnity labelling capability.
44
Using detergent-solubilized membranes that retained the
allosteric modulation of GABAA-R radioligand binding by
etomidate, the Richard Olsen lab puriﬁed to homogeneity
the GABAA-R protein from bovine cerebral cortex and
photoafﬁnity labelled the pooled protein (several hundred
pmol) with [
3H]azietomidate, leading to a single peak of
radioactive protein at ca. 55 kDa, which was shown by
mass spectrometry and Western blotting to contain
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a4) subunits. Edman degradation microsequencing of pro-
teolytic fragments puriﬁed on high performance liquid
chromotogrpahy (HPLC) by the Jon Cohen lab allowed
identiﬁcation of the labelled amino acids. The residues that
were labelled do not appear to be nonspeciﬁcally tagged.
The same results have now been obtained on numerous
occasions; alkyl azides are not particularly reactive with
Met residues, and several more reactive residues as well as
two other methionines in the region near our two identiﬁed
amino acids were not reactive.
The residues labelled were M236 in the M1 domain of
the alpha subunits (a1, 2, 3, and 5 were all the same in the
relevant peptides) and M286 in the M3 domain of the beta
subunits (also identical in b1, 2, and 3). The attachment
sites for etomidate were thus identiﬁed as aM1-11’ (M236)
and bM3-4’ (M286) (Table 1).
29 The latter is the same as
one of the two identiﬁed by Mihic et al. for anesthetic
alcohols and volatile agents.
13 The former had not been
described previously for anesthetic interactions. Figure 1
shows a 3-D model of the heteropentameric GABAA-R with
the GABA and BZ sites at subunit interfaces in the extra-
cellular domain and etomidate sites in the transmembrane
domain.
29 The BZ sites are modiﬁed GABA sites located at
a different subunit interface, that is, homologous residues
corresponding to agonist binding pocket loops in the protein
at the two b/a interfaces for GABA binding are involved in
BZ binding at the single a/c interface.
8,11,45
Interaction of other general anesthetics
with azietomidate labelling sites
The Table summarizes the studies with other chemical
classes of general anesthetics. The intravenous agent,
propofol, with a very similar pharmacological proﬁle was
able to inhibit the labelling of GABAA-R with azietomidate
at anesthetic concentrations, but only partially, even when
present in large excess over the etomidate. This partial
inhibitionwasevidentonbothlabelledresidues,asshownby
sequencing. The binding is not mutually exclusive, although
it could involve overlapping sites. We conclude that it indi-
cates an allosteric interaction.
46 A similar partial inhibition
was seen for a series of pharmacologically active barbitu-
rates, also apparently allosteric.
46 In addition, the anesthetic
neurosteroids at appropriate concentrations did not inhibit
azietomidate labelling but rather enhanced it. This proves
that the steroid site does not coincide with the etomidate
binding pocket and interacts allosterically.
36 On the other
hand, the volatile agent, isoﬂurane, showed a smooth inhi-
bition curve down to zero and thus could possibly reﬂect
competitive inhibition. However, the alcohols, n-octanol
(10-1000 lM) and EtOH (1-1000 mM), failed to interact
with azietomidate labelling, neither enhancing nor inhibit-
ing.
46 We have suggested another site for pharmacological
actions of EtOH at low concentrations on GABAA-R.
16
Homology modelling
Computer-enhanced electron microscope images of the
Torpedo nicotinic acetylcholine receptor
47 and the water-
soluble acetylcholine binding protein
48 allowed homology
modelling of the GABAA-R and positioned the two
etomidate labelled residues sufﬁciently close to each other
(about 10 A ˚ ´) in the transmembrane domain to allow us to
propose a single binding pocket at the interface between
aM1 and bM3 (Li et al., 2006,
29 Electronic Supplementary
Material). This intersubunit etomidate binding pocket
(Fig. 2) would be present in two (identical) copies per
Table 1 Identiﬁed amino acids interacting with general anesthetics in GABAA-Rs
Residues
* a/b M1(-2’) a M1(11’) a M2(15’) b M2(15’) b M3 (4’)
References 14,54,55 29,36,46 13,25,26,39-43 13,31,37,38,53 29,36,46
Etomidate ??  ??
Propofol ??  ??
Volatile agents, e.g., isoﬂurane  ??  ?
Steroids, e.g., alphaxalone ?? ––?
Barbiturates ?? ?
Alcohols – – ??–
Knock-in  ??
*Residues are identiﬁed by the convention for pentameric/cys-loop ligand-gated ion channel receptors designating the ﬁrst amino acid in the
transmembrane helix as 1’ and consecutively through the membrane.  Knock-in refers to whether or not a knock-in mouse for this residue has
been generated and shows evidence consistent with a role in anesthetic action. A plus sign (?) signiﬁes that the general anesthetic listed in rows
at left of matrix is identiﬁed with the amino acid residue listed in columns at the top. A minus sign (-) indicates that there is negative evidence
for such an identiﬁcation. The double dagger () indicates that there is no conclusive evidence for or against; this includes topics that have not
been determined. GABAA-Rs = gamma-aminobutyric acid type A receptors
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123pentamer at the same subunit interfaces (b?/a-) where
GABA binding occurs in the extracellular domain. This
seems a suitable position for allosteric modulation, espe-
cially relevant to the quaternary twist allosteric model for
the pentameric ligand-gated ion channel receptors.
49 The
presence of only one kind of etomidate site
29 suggests that
both enhancement of GABA and direct gating by etomidate
involve this one site. This is consistent with modelling of
functional data following the Monod-Wyman-Changeux
2-state allosteric model.
50
Jansen & Akabas
51 used ‘‘cysteine scanning accessibility
measurements’’ and cross-linking to align the M2 and M3
helices of the nicotinic acetylcholine receptor and used
homology GABAAR to allow a ﬁxed setting of the helical
wheels relevant to our proposed etomidate site.
29,36 Bali
et al.
52 continued in this vein using cysteine substituents to
align the M1 and M3 helices of GABAAR, reﬁning the
helical wheel orientations (Fig. 1C). This showed our two
etomidate residues, aM1-11’ and bM3-4’, to be very close
and consistent with a single intersubunit anesthetic binding
pocketatthea/binterface.OnecanalsoseethatthebM2-15’
is not directly adjacent to the etomidate binding pocket but
also is not very distant, and so it could possibly move into
closer contactwith aM1-11’ and bM3-4’. On the other hand,
the two residues implicated in steroid direct gating action
35
(Fig. 1C)areondifferentsidesofthehelicesandcouldnotbe
part of a single binding pocket due to the distance between
them. Those residues implicated in steroid enhancement of
GABA are not shown on this helix but would not overlap
with the etomidate enhancement site we deﬁned.
Biochemistry and electrophysiological testing of models
derived from residue identiﬁcation and modelling
Work in the lab of Harrison
25 as a follow-up to Mihic
et al.
13 showed that the GABAA-R aM2-15’ involvement
for volatiles was sensitive to the volume of the amino acid
at that position, consistent with a binding pocket. Follow-
up work in the lab of Harris
26 showed that an alcohol
sulfhydryl analogue, propanethiol, could be covalently
attached to aM2-15’ when substituted by cysteine, leading
to persistent enhancement of GABA responses. This was
even more dramatically demonstrated for b2M2-15’, which
could be modiﬁed by the alcohol, octane methanethiosul-
fonate, when mutated to cysteine to produce a covalent
attachment showing irreversible potentiation
53 consistent
with a long-chain alcohol binding site. The binding of the
octanol analogue could be inhibited by n-octanol, and the
modiﬁcation was able to alter modulation of GABA
Fig. 1 Three-dimensional views of the c-aminobutyric acid type A
receptors (GABAAR) homology model from different perspectives
(A,B) and helical wheel representation of the transmembrane regions
at the etomidate binding domain at the b/a interface (C). A) Three-
dimensional view of the GABAAR homology model (b3, cyan; a1,
yellow; c2, green) from a perspective outside the membrane looking
down the channel or B) from a perspective parallel to the membrane
surface. Modiﬁed from Li et al. (2006)
29 in which our homology
model is based roughly on the nicotinic acetylcholine receptor cryo-
EM derived structure (PDB:2BG9),
47 modiﬁed by helical alignment
data from Jansen & Akabas (2006).
51 Pockets in the vicinity of the
etomidate (maroon), GABA (purple), and benzodiazepine (red)
binding sites are shown as Connolly surfaces. C) Helical wheel
representation of the GABAAR b/a interface in the trans-membrane
domain illustrating the proposed binding site for etomidate (modiﬁed
from Li et al., 2009).
36 The model illustrates the orientation of
residues from a homology model built on the nicotinic acetylcholine
receptor cryo-EM derived structure,
47 with the residues in aM1 and
bM3 photolabelled by [
3H]azietomidate (circled residues in green)
contributing to a common binding pocket at the b/a interface. Also
included: the position in bM2 (N265) that functions as a determinant
of etomidate/azietomidate anesthetic potency in vivo (pink)
37,38,62; the
residues in aM1 and bM3 identiﬁed as sensitivity determinants for
direct activation by neurosteroids (boxed residues in yellow)
35; and
the positions in aM1 and bM3 that can form intersubunit cross-links
when mutated to Cys (red and orange)
52,58
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123function by butanol and isoﬂurane, with some reduction of
modulation by alphaxalone and ﬂunitrazepam, but not
pentobarbital.
53 Homology modelling in which GABAA-R
transmembrane helices were aligned, as found in the nic-
otinic acetylcholine receptor,
47 suggested that these two
residues, a or b M2-15’ and M3-4’, could be found in a
single intrasubunit pocket.
13,18 This supports the idea that
the M2-15’ residue could be a binding site for long-chain
alcohols and maybe volatile agents and could be sensitive
to allosteric modulation by etomidate, propofol, and pos-
sibly other anesthetics. However, residues identiﬁed by
mutagenesis alone could also be involved ‘‘merely’’ in
allosteric transduction.
Work in the lab of Olsen as follow-up to Carlson et al.
(2000)
14 found mutations at this M1 residue, a or bM1
(-2’), to alter rates of desensitization to GABA agonists and
allosteric modulators.
54 Mutations of b2M1(-2’) to a series
of residues differing in volume showed altered gating
kinetics consistent with a binding pocket.
55 These muta-
genesis studies also showed distinctive effects on
anesthetic direct gating vs enhancement of GABA, con-
sistent with two separate sites of action. However, the lack
of chemical speciﬁcity for the modulators involved is more
consistent with an allosteric transduction site than a bind-
ing pocket.
Mutagenesis analysis of the two etomidate binding res-
idues of Li et al. (2006)
29 has been studied by our lab
56 and
collaborator, Stu Forman. The ﬁrst study replaced aM236
or bM286 with trp. Either mutation led to reduced allo-
steric modulation of GABA by etomidate, with increased
spontaneous openings, GABA left-shift, and increased
direct gating by etomidate,
57 which we interpret as being
consistent but not conclusive with the theory that the res-
idues are in a binding pocket. The second study replaced
the two etomidate residues with cysteine. With radioligand
binding, we found that large but not small sulfhydryl
reagents reacted with the a1M236 (M1-11’) in a manner
that irreversibly prevented etomidate modulation of
GABAA-R ligand binding; furthermore, the reaction with
the sulfhydryl reagents was protected by excess etomidate
in the tube.
56 Stewart & Forman (2009)
58 used electro-
physiology with a1b2c2 GABAA-R to show that mutation
b2M286C (M3-4’) and b2N265C (M2-15’) could react
with the sulfhydryl reagent, p-Cl mercuribenzene sulfo-
nate, to eliminate etomidate modulation of channel
function, but that excess etomidate protected the M286
residue, but not the N265 residue, from reaction with the
sulfhydryl reagent. This is consistent with the etomidate
residues identiﬁed by afﬁnity labelling as being part of an
anesthetic binding pocket.
Summary of residues in GABAA-Rs identiﬁed
as necessary for anesthetic action
Homology modelling with the data of Unwin
47 as a tem-
plate suggested that the two etomidate binding residues
could be part of a single class (two copies per pentamer) of
intersubunit binding pocket (Fig. 2).
29 This is also con-
sistent with a single site for etomidate direct gating and
modulation of GABA current, as suggested by Ru ¨sch et al.
(2004).
50 Crosslinking studies of cysteine-substituted
helical residues in the Akabas lab
51,52 were totally con-
sistent with this model, because residues that can crosslink
between aM1 and bM3 position our etomidate residues,
aM236 and bM286, nearly adjacent to each other
(Fig. 1C).
29,36 The transmembrane intersubunit pocket
(Fig. 2) appears well situated to allosterically modulate the
quaternary twist conformational change produced to gate
the channel after binding of agonist to its site in the same b/
a subunit interface of the extracellular domain 50 A ˚ ´
Fig. 2 The intersubunit anesthetic binding pocket in the c-aminobu-
tyric acid type A (GABAA) receptor transmembrane domain
identiﬁed by photoafﬁnity labelling with [
3H]azietomidate.
29 The
identiﬁed residue, M236, in the M1 domain of the a subunit is situated
nearly adjacent to the identiﬁed residue, M286, in the M3 domain of
the b subunit. Reproduced with permission from: Li GD, Chiara DC,
Sawyer GW, Hussain SS, Olsen RW, Cohen JB. Identiﬁcation of a
GABAA receptor anesthetic binding site at subunit interfaces by
photolabelling with an etomidate analog. J Neurosci 2006; 45: 11599-
605
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123directly above (Fig. 1). Nevertheless, the general anes-
thetics, desﬂurane, halothane, and propofol, were shown to
inhibit channel function
59 of another pentameric ligand-
gated ion channel, the bacterial GLIC channel,
60 and
binding of these anesthetics was shown in x-ray crystal
structures to occur at intrasubunit pockets in the trans-
membrane domain (P-J Corringer, MAC2010 symposium).
The intersubunit pocket between bM3 and aM1 for
etomidate seems highly likely at this point. It remains
unclear whether the other residue labelled by Mihic et al.
(1997)
13 at M2-15’ is part of this pocket. This residue was
not afﬁnity labelled by azietomidate. In our structural
model, it is located sufﬁciently close to potentially partic-
ipate in the binding pocket (Fig. 1C).
29,36 Nevertheless,
cysteine substitution of the three residues and inactivation
by cysteine reagents revealed that etomidate occupancy
was able to protect the cysteine reaction at a1M236C and
b2M286C, but not at b2N265C, suggesting that the ﬁrst
two residues, but not the last, are in the etomidate binding
pocket.
58 This had been suggested earlier by Bali &
Akabas
61 who showed that propofol occupancy could
protect from cysteine reagent inactivation at aM286C, but
not at aN265C. The M2-15’ residue is clearly very
important for anesthetic action. If it is part of the inter-
subunit pocket (aM1/bM2/bM3), it is unlikely that it would
also be part of an intrasubunit pocket (aM1/aM2/aM3 or
bM1/bM2/bM3), but this remains to be seen. It could differ
for the different chemical classes of general anesthetics.
There is evidence
26 that propanol can bind to the aM2-15’
and octanol
53 can bind to the bM2-15’, but these com-
pounds do not interact with the etomidate binding residues,
aM1-11’ and bM3-4’ (Li et al.).
Hosie et al.
35 identiﬁed residues in aM1 and aM4 nee-
ded for neurosteroid enhancement of GABAA-R and two
residues in aM1 and bM3 needed for direct steroid gating,
which were proposed to be part of a single intersubunit
anesthetic steroid site. However, those two residues are not
positioned near each other in the helical wheels generated
by models of the intersubunit etomidate site consistent with
the cysteine substitution cross-linking data
29,52 and con-
sistent with our demonstration that the GABAA-R steroid
ligands do not inhibit azietomidate labelling but rather
enhance the binding in a pharmacologically speciﬁc man-
ner.
36 Our study of additional chemical classes of general
anesthetics (Table 1) showed that propofol inhibited azie-
tomidate labelling, but only partially, and thus probably
allosterically.
46 Likewise, barbiturates partially inhibited
azietomidate labelling in a pharmacologically and stereo-
speciﬁc manner, thus were probably allosteric. The volatile
agent, isoﬂurane, gave a complete and possibly competitive
inhibition of azietomidate labelling, while two alcohols,
n-octanol and EtOH, at pharmacologically active concen-
trations gave no inhibition or enhancement of azietomidate
labelling of brain GABAA-R.
46 Taken together, the data on
[
3H]azietomidate labelling suggest that we have directly
identiﬁed amino acids in the contact point and binding
pocket for a general anesthetic in a relevant biological
target of action, the GABAA-R protein in the mammalian
brain. This information and future studies on the topic
should provide a path to development of safer, more
effective, and more selective general anesthetics.
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